云南白药:云核医药的INR102注射液获得药物临床试验批准

格隆汇资讯
08 Apr

格隆汇4月8日丨云南白药(000538.SZ)公布,公司全资子公司云核医药(天津)有限公司(简称“云核医药”)于近日收到国家药品监督管理局下发的《药物临床试验批准通知书》(通知书编号:2025LP01012),经审查,云核医药的INR102注射液(以下简称“本品”)临床试验申请符合药品注册的有关要求,同意本品开展前列腺癌的临床试验。本品为云核医药研发的化学1类放射性治疗类创新药,拟用于治疗已经接受...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10